Description du projet
La technologie de «photocopie» de l’ADN accélère le développement de vaccins
La pandémie de SRAS-CoV-2 a mis en évidence le besoin urgent de développer des vaccins. Pour améliorer l’efficacité et la rapidité de la conception des vaccins, le projet BIOCOPY, financé par l’UE, a mis au point une technique brevetée qui peut considérablement faire progresser les processus de développement et ce, à moindre coût. La technique fait appel à une surface recouverte d’ADN pour générer d’autres biomolécules (ADN, ARN ou protéines) qui peuvent servir de cibles aux agents pathogènes et être exploitées pour le développement de vaccins. La nature haut débit de la méthode permet d’analyser des centaines de protéines en même temps, ce qui facilite une rotation rapide.
Objectif
"BioCopy is a spin-off company borned in the University of Freiburg. We have developed an innovative, patented technique to copy biomolecules analogous to a photocopier. A DNA-coated surface is used as copy template. By supplying different biochemical ""copy mixes"", either a DNA, a RNA or a protein copy is generated. After the copy process, the copied biomolecules can be analyzed label-free for their specific binding to target molecules and recovered as potential candidates for a future use as therapeutics or diagnostics. The BioCopy technology completely opens up new dimensions for drug development, vaccines, antibodies, enzymes, catalysts, bioactive coatings, and biosensors and it has are more than 40 future applications. We plan to offer 3 products and services to pharma and biotech companies, related with high- output and cheaper molecular biology screenings. The most promising line is the tailor-made discovery of vaccine candidates within two days. This will have a disruptive character, because the first generation of a vaccine is a billion-dollar market, projected to rise $60 billion on 2019, with 11% growth per annum, and to $100 billion by 2025. BioCopy will provide vaccine candidates to pharmaceuticals, obtaining revenues through upfront, milestone and royalty payments, and they will be responsible for the vaccine´s clinical development, approval and distribution. The multi-awarded BioCopy team covers business know-how and expertise in biology, physics, manufacturing systems engineering, assay development and microsystems technology. BioCopy aims to contribute to the European challenges related with advanced biotechnology applications in pharma sector, and to increase the technological transfer from the academic world into the manufacturing sector. During phase 1 we will build up a detailed business plan and a feasibility study, describing all the needed activities in order to reach BioCopy commercialization. We will need about €2.5M in phase 2."
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesgeneticsRNA
- natural sciencesbiological sciencesmolecular biology
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
79312 EMMENDINGEN
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.